This launch gives employers a more flexible way to support safe, effective obesity care
Substantial clinical research base, growing research adoption
GLP-1 drugs like Ozempic, Wegovy, Mounjaro and Zepbound transform care for obesity and diabetes
- Thng hiu: Dr.Lacir - Quy cch: hp 30 vin nang mm - Cng dng chnh: Sng da, m nm, h tr ci thin suy gim ni tit t n, h tr lm p da - Sn phm thuc cng ty c phn Quc T Dopharma - Nh my sn xut: Cng ty dc phm Oshii Glutathione 600 Dr Lacir gim nm, tn nhang h tr ci thin tnh trng suy gim ni tit t n sn phm c ngun nguyn liu nhp khu t Nht Bn
GLP-1 receptor agonists are licensed in the UK for type 2 diabetes mellitus and specific weight management indications, not for cognitive impairment or dementia GLP-1 receptors are present in brain regions involved in memory and learning, prompting research into potential neuroprotective effects Ongoing clinical trials, including studies of semaglutide in Alzheimer's disease, are examining whether these medications benefit cognitive function Common adverse effects include gastrointestinal symptoms